Display options
Cite
Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, et al. Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol. 2021;12(9):800-807doi: 10.5306/wjco.v12.i9.800.
Sánchez-Valledor, L. F., Habermann, T. M., Murrieta-Alvarez, I., Córdova-Ramírez, A. C., Rivera-Álvarez, M., León-Peña, A., Cantero-Fortiz, Y., Olivares-Gazca, J. C., Ruiz-Delgado, G. J., & Ruiz-Argüelles, G. J. (2021). Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center. World journal of clinical oncology, 12(9), 800-807. https://doi.org/10.5306/wjco.v12.i9.800
Sánchez-Valledor, Luisa Fernanda, et al. "Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center." World journal of clinical oncology vol. 12,9 (2021): 800-807. doi: https://doi.org/10.5306/wjco.v12.i9.800
Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, Córdova-Ramírez AC, Rivera-Álvarez M, León-Peña A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol. 2021 Sep 24;12(9):800-807. doi: 10.5306/wjco.v12.i9.800. PMID: 34631443; PMCID: PMC8479346.
Copy Download .nbib Format: NLM
Share it on

World J Clin Oncol. 2021 Sep 24;12(9):800-807. doi: 10.5306/wjco.v12.i9.800.

Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center.

World journal of clinical oncology

Luisa Fernanda Sánchez-Valledor, Thomas M Habermann, Iván Murrieta-Alvarez, Alejandra Carmina Córdova-Ramírez, Montserrat Rivera-Álvarez, Andrés León-Peña, Yahveth Cantero-Fortiz, Juan Carlos Olivares-Gazca, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Argüelles

Affiliations

  1. Escuela de Medicina, Universidad de las Américas Puebla, Cholula 72810, Puebla, Mexico.
  2. Department of Medicine, Division of Hematology, Mayo Clinical and Mayo Foundation, Rochester, MN 55905, United States.
  3. Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla 72530, Mexico.
  4. Escuela de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, Mexico.
  5. Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla 72530, Mexico. [email protected].

PMID: 34631443 PMCID: PMC8479346 DOI: 10.5306/wjco.v12.i9.800

Abstract

BACKGROUND: The outcomes of Hodgkin´s lymphoma (HL) in México have not been widely reported. Simplified and affordable treatments have been adopted in middle-income countries.

AIM: The aim was to evaluate long-used therapies for HL in México in a long-term basis.

METHODS: In a 34-year time period, 88 patients with HL were treated at a single institution in México. Patients were treated with adriamycin bleomycin vinblastine and dacarbazine (ABVD) or mechlorethamine, vincristine, procarbazine, and prednisone (MOPP). Relapsed or refractory patients were given ifosfamide, carboplatin, and etoposide (ICE) followed by autologous or allogeneic stem cell transplants.

RESULTS: Thirty-seven women and 51 men were included; the median age was 29 years. Patients were followed for a mean of 128 mo. The 310-mo overall survival (OS) was 83% for patients treated with MOPP and 88% for those treated with ABVD. The OS of patients who received autologous stem cell transplantation was 76% (330 mo)

CONCLUSION: HL may be less aggressive in Mexican population than in Caucasians. Combined chemotherapy renders acceptable results, regardless of clinical stage.

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Keywords: ABVD chemotherapy; Hodgkin; Lymphoma; Treatment

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no conflicting interests.

References

  1. Invest New Drugs. 2015 Aug;33(4):992-1001 - PubMed
  2. Am J Hematol. 2016 Jun;91(4):434-42 - PubMed
  3. Int J Ayurveda Res. 2010 Oct;1(4):274-8 - PubMed
  4. J Glob Oncol. 2019 Nov;5:1-19 - PubMed
  5. Acta Haematol. 2018;140(2):114-120 - PubMed
  6. Br J Haematol. 2020 Apr;189(1):122-127 - PubMed
  7. Rev Bras Hematol Hemoter. 2017 Oct - Dec;39(4):325-330 - PubMed
  8. J Clin Med. 2021 Mar 08;10(5): - PubMed
  9. Acta Haematol. 2020;143(6):552-558 - PubMed
  10. Cell Transplant. 2020 Jan-Dec;29:963689720975397 - PubMed
  11. Blood. 2018 Apr 12;131(15):1629-1630 - PubMed
  12. Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):522-529 - PubMed
  13. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):444-451 - PubMed
  14. Support Care Cancer. 2021 Sep;29(9):4987-4996 - PubMed
  15. Hematology. 2020 Dec;25(1):366-371 - PubMed
  16. J Clin Oncol. 2015 Jun 10;33(17):1936-42 - PubMed
  17. N Engl J Med. 2016 Jun 23;374(25):2419-29 - PubMed
  18. Salud Publica Mex. 2016 Apr;58(2):291-5 - PubMed
  19. Medicine (Baltimore). 2020 Dec 4;99(49):e23412 - PubMed
  20. Hematology. 2020 Dec;25(1):156-159 - PubMed
  21. BMJ. 2017 Oct 4;359:j4530 - PubMed
  22. Cancers (Basel). 2021 Feb 07;13(4): - PubMed

Publication Types